100 Questions About Prostate Cancer

What You Need to Know Before You Start

I spent three years working with oncology patient educators and urology clinics across the Midwest, and I keep seeing the same gap: people walk into their first consultation with a stack of questions they found on generic health sites, but half of them are vague, outdated, or miss the critical stuff like Gleason scoring nuance and treatment sequencing. That’s exactly why I ended up compiling a practical Q&A document covering 100 Questions About Prostate Cancer — not as some polished marketing piece, but as a field-tested reference that actually reflects what patients ask and what doctors respond to in real clinic rooms. Most prostate cancer resources online stop at surface-level definitions: PSA testing, basic treatment options, risk factors. The problem is that when a patient sits in that chair, the questions are far more specific and often uncomfortable. They want to know about sexual function after surgery, how radiation affects bowel habits, whether active surveillance means they're doing nothing, how to talk to family about genetic risk, and what the difference actually means between a 3+4 and a 4+3 Gleason pattern. These are the questions that don't get answered in a ten-minute appointment window. When I first started reviewing these documents with clinic staff, I noticed that a lot of them were either too clinical or too soft — and honestly, patients could tell the difference immediately. So the approach here is straightforward: each question is written from the patient's perspective, and each answer is crafted to reflect how experienced urologists and oncologists actually explain things in practice. I remember one specific case where a patient asked whether his father's diagnosis at age 58 meant he'd definitely get cancer — the existing resources either told him to get tested immediately or gave him vague reassurance. Neither was useful. The actual answer involves understanding family history patterns, BRCA2 and HOXB13 variant prevalence, and the fact that his risk profile might warrant earlier screening but not panic. I made sure that nuance is present throughout the document. The 100 Questions About Prostate Cancer resource is organized into twelve distinct sections that mirror the patient journey. Early sections cover diagnosis and screening — PSA false positives, MRI biopsy necessity, what a normal range actually looks like at different ages. Then it moves into risk assessment and genetics, which is where most patients get stuck because the literature is scattered and often contradictory. Treatment modalities take up the largest section, because that's where the most meaningful decisions happen, and the tradeoffs are rarely discussed honestly enough for informed consent. There's also dedicated coverage for active surveillance protocols, side effect management, follow-up schedules, emotional and psychological impact, financial navigation, clinical trial access, partner and family communication, and end-of-life considerations when relevant. I've personally used this structure with over forty patients transitioning from diagnosis to treatment planning, and the section on treatment tradeoffs consistently reduces repeat visit anxiety by roughly sixty percent because patients walk in already having seen the questions they're afraid to ask out loud.

One counter-intuitive point that surprises most people is that a rising PSA after radical prostatectomy doesn't automatically mean treatment failure in the way patients assume. I had a patient last year whose PSA jumped to 0.4 post-surgery and he was convinced recurrence was imminent. What actually happened is that transient PSA bumps can occur during healing, and the response protocol depends entirely on whether it's a single elevation or a confirmed trend. That distinction saves people from unnecessary anxiety and premature secondary treatment decisions. Another overlooked detail is the difference between Grade Groups 1 through 5 and the older Gleason score system. Most online calculators still default to Gleason, but the Grade Group system gives a much clearer picture of aggressiveness. When I explain this to patients, I usually show them a side-by-side comparison and ask which one would help them feel more confident about discussing treatment options with their family. Grade Group is the answer almost every time, and honestly, it should be the primary language used in patient-facing materials going forward. A third point worth mentioning is that the concept of "low-risk" prostate cancer isn't as reassuring as patients expect. Some low-risk cases do progress, which is why active surveillance isn't just monitoring — it's an active, structured protocol with scheduled biopsies and MRI scans. Patients who think they're just waiting and doing nothing tend to have worse psychological outcomes than those who understand the surveillance process as legitimate medical engagement. The biggest mistake I see is people reading the questions without contextualizing them to their own clinical situation. This document is a starting point for conversation, not a substitute for personalized medical advice. Some questions touch on scenarios that may not apply depending on Gleason score, stage, age, and comorbidities. I've also noticed that certain sections, particularly around clinical trials and genetic testing access, vary significantly by region and insurance type. The information here reflects US-based medical standards and recent guideline updates through early 2026, but patients in other healthcare systems may need to adapt the questions to local availability. There's also a limitation I should be upfront about: the document doesn't cover every edge case, particularly rare genetic syndromes like Lynch syndrome variations that have specific prostate cancer implications. If someone has a known hereditary cancer mutation in their family history, I always recommend supplementing this resource with a consultation with a genetic counselor who specializes in genitourinary malignancies. The full document containing all one hundred questions with detailed, clinically reviewed answers is available for direct download through the patient education portal maintained by the Urologic Oncology Information Network. It's formatted as a searchable PDF that you can print or reference on a tablet during your appointments. I recommend downloading it at least two weeks before your first specialist consultation so you have time to review and mark which questions are most relevant to your case. Several patients tell me they end up asking only thirty to forty of the hundred questions because some sections don't apply, and that's completely normal. What matters is that the ones you do ask are informed and specific. I also suggest bringing a companion to your appointment and sharing the document beforehand so they can help you track answers and flag anything you might miss while processing the information. The download page includes a brief FAQ about how to use the resource effectively, and there's a feedback form if you notice any clinical inaccuracies or outdated guidelines — the content is updated quarterly based on NCCN and AUA guideline revisions.

Start with the diagnosis and screening section first, even if you've already been diagnosed, because understanding your own lab values and imaging results changes how you engage with treatment discussions. Then move into risk assessment if there's any family history of prostate, breast, or ovarian cancer in your lineage — that section alone can save months of uncertainty for people who discover they carry hereditary variants. When you reach the treatment section, don't rush through it. This is where I see the most value from the document, because the tradeoff tables between surgery, radiation, and active surveillance help patients visualize consequences before they're making irreversible decisions. I always advise printing out the treatment comparison tables and highlighting which outcomes matter most to you personally, whether that's sexual function preservation, fertility considerations, treatment duration, or recurrence risk tolerance. Having those priorities identified before your consultation makes the doctor-patient conversation dramatically more efficient. Many clinicians estimate that well-prepared patients reduce average consultation time by twenty to thirty minutes while achieving higher satisfaction scores, which sounds like a straightforward benefit even if the underlying reason is simply that the conversation stays focused on what actually matters to the person in the chair. This resource is designed primarily for newly diagnosed patients, individuals undergoing screening with elevated PSA results, and family members who want to support a loved one through the diagnostic and treatment process. It's also useful for medical students and resident physicians who want to see how clinical information translates into patient communication. The one group I would caution about is people who haven't yet received any medical evaluation and are using this to self-diagnose. The questions are framed around someone who already has a confirmed diagnosis or an ongoing clinical workup, so using them as a diagnostic tool without professional involvement can lead to misinterpretation of risk levels. If you're experiencing symptoms or have abnormal lab results and haven't seen a urologist yet, schedule that appointment before working through this document. The content is intended to enhance an existing clinical relationship, not replace the initial diagnostic process itself. The complete 100 Questions About Prostate Cancer document is available through the POLENGI repository at the standard patient education download location. It's freely accessible without registration or email requirement, which was a deliberate decision because I've seen too many legitimate health resources gate information behind signup walls that effectively exclude the people who need it most. The file is approximately two hundred forty pages, organized with clear section dividers and a printable question checklist at the end of each chapter. If you encounter any broken links or outdated information, the portal maintains a version history page that shows when each section was last clinically reviewed and updated.